Bruker announces NIST order for AVANCE III 900 NMR spectrometer

Bruker Corporation (NASDAQ: BRKR), the leader in analytical magnetic resonance instrumentation, today announces a major order from the National Institute of Standards and Technology (NIST) for its ultra-high field AVANCE™ III 900 US2 NMR spectrometer. This purchase, made through a competitive award process and funded by the American Recovery and Reinvestment Act (ARRA), will be used by NIST's Macromolecular Structure and Function Group to develop novel NMR methods and models for analysis of the molecular structure and dynamics of biological macromolecules and complexes formed by these molecules. The Research projects will support NIST's measurement and standards programs for healthcare and biomanufacturing.

Based on Bruker's very successful 900 MHz (21.2 Tesla) actively-shielded US² magnet, the AVANCE III 900 offers one of the highest magnetic fields for NMR applications. The 900 US2 magnet combines Bruker's proven proprietary UltraShield™ active-shielding and UltraStabilized™ sub-cooling technologies. The result is the most reliable 900 MHz magnet for NMR applications with a relatively small stray field and footprint for straight-forward installations.

NIST's focus on precise measurement methods to define the structure, thermodynamics and kinetics of protein-protein and protein-nucleic acid interactions at the molecular level requires an NMR system with the highest sensitivity and stability for long-term measurements. The AVANCE III digital rf architecture delivers such performance with an unprecedented level of digital control, speed, flexibility and exceptionally pure NMR frequency generation. The AVANCE III 900 US2 system includes Bruker's high-sensitivity CryoProbe™ technology enabling NIST researchers to perform measurements on very small quantities of sample.

SOURCE Bruker Corporation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
The design of immunogens for the SARS-CoV-2 spike protein using structure-guided epitope grafting and scaffolding methods